Learn how tesamorelin CJC 1295 ipamorelin work together, typical stack dosages, differences, safety, and legal status. Informational guide for US researchers.
Tesamorelin, CJC-1295, and ipamorelin are three peptides that stimulate growth hormone release through different pathways. Tesamorelin is FDA-approved for HIV-associated lipodystrophy, while CJC-1295 and ipamorelin are not approved for human use and are sold as research chemicals. Stacking these peptides is not a standard medical practice, and anyone considering such a combination should consult a licensed healthcare professional.
What Are Tesamorelin, CJC-1295, and Ipamorelin?
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is approved by the FDA as Egrifta for the treatment of excess abdominal fat in adults with HIV and lipodystrophy. Tesamorelin works by binding to GHRH receptors in the pituitary gland, prompting the release of growth hormone.
CJC-1295 is also a GHRH analog. It comes in two forms: CJC-1295 with DAC (drug affinity complex) and CJC-1295 without DAC, often called mod GRF 1-29. The DAC form extends the half-life by binding to albumin in the blood, while the no-DAC form has a shorter half-life similar to natural GHRH.
Ipamorelin is a selective growth hormone secretagogue. It mimics ghrelin, a hormone that stimulates hunger and GH release. Unlike some other secretagogues, ipamorelin is studied for its ability to increase GH without significantly raising cortisol or prolactin levels.
Many researchers compare cjc-1295 ipamorelin vs tesamorelin to understand differences in half-life, selectivity, and approved uses.
How Do These Peptides Work Together?
Tesamorelin and CJC-1295 both act on GHRH receptors, while ipamorelin acts on ghrelin receptors. Because they target different receptors, combining them can produce a synergistic effect on growth hormone release. This synergy is a key reason why researchers study these peptides together.
Each peptide has a different half-life, which affects how often it must be injected. Tesamorelin has a short half-life and is usually injected daily. CJC-1295 with DAC lasts for days, while ipamorelin lasts about two hours. These differences are important when designing a stacking protocol.
However, no large clinical trials have tested this specific three-peptide combination. Most evidence comes from animal studies or small human trials of individual peptides. The long-term safety and efficacy of stacking tesamorelin, CJC-1295, and ipamorelin are unknown.
Tesamorelin vs. CJC-1295 vs. Ipamorelin: Key Differences
The table below summarizes the main differences between these three peptides.
| Peptide | Mechanism | Half-Life | FDA Status | Primary Use/Research |
|---|---|---|---|---|
| Tesamorelin | GHRH receptor agonist | ~26–38 minutes | Approved (Egrifta) for HIV lipodystrophy | Reduction of visceral fat; GH stimulation |
| CJC-1295 with DAC | GHRH receptor agonist | ~6–8 days | Not approved | Research on sustained GH release |
| CJC-1295 without DAC | GHRH receptor agonist | ~30 minutes | Not approved | Research on pulsatile GH release |
| Ipamorelin | Ghrelin receptor agonist | ~2 hours | Not approved | Selective GH release; research on body composition |
When evaluating tesamorelin vs ipamorelin vs cjc 1295, the most obvious difference is FDA approval status. Tesamorelin is the only one with an approved medical indication. CJC-1295 and ipamorelin are sold strictly for research purposes and are not intended for human consumption.
Potential Stacking Protocols and Dosages
There is no standard dosage for a tesamorelin, CJC-1295, and ipamorelin stack. Any numbers mentioned in research or online forums are not clinically validated. The following information is for educational purposes only and should not be taken as medical advice.
Typical research dosages for individual peptides are:
- Tesamorelin: 1–2 mg subcutaneously once daily. The FDA-approved dose for HIV lipodystrophy is 2 mg daily.
- CJC-1295 without DAC: 100–200 mcg subcutaneously 1–3 times daily.
- CJC-1295 with DAC: 1–2 mg subcutaneously once or twice weekly.
- Ipamorelin: 100–200 mcg subcutaneously 1–3 times daily.
Some sources describe a tesamorelin #ipamorelin cjc 1295 blend dosage, but these blends are not standardized and may contain unknown quantities. A cjc-1295 ipamorelin tesamorelin stack dosage usually involves lower doses of each peptide to avoid excessive growth hormone release and side effects.
For those researching cjc-1295 no dac ipamorelin tesamorelin, the no-DAC form of CJC-1295 is often preferred for more pulsatile GH release, while the DAC form provides a continuous baseline.
Safety, Side Effects, and Legal Status
Tesamorelin is generally well-tolerated in clinical trials. Common side effects include injection site reactions, joint pain, muscle pain, swelling, and increased blood sugar. Tesamorelin can also cause an allergic reaction, and it may increase the risk of diabetes. It is not approved for weight loss or anti-aging purposes.
CJC-1295 and ipamorelin have not been approved by the FDA for any human use. They are sold as research chemicals and are labeled "not for human use." Potential side effects reported by users include headache, flushing, dizziness, increased hunger, and injection site reactions. Because these peptides are not regulated, the purity and actual content of products sold online are not guaranteed.
In the United States, tesamorelin requires a prescription. CJC-1295 and ipamorelin are not approved for human consumption, and it is illegal to sell them for that purpose. Anyone considering their use should consult a licensed healthcare professional and be aware of the legal and health risks.
Research and Clinical Evidence
Clinical evidence for the three-peptide stack is limited. Tesamorelin has been studied in large trials for HIV-associated lipodystrophy, showing reductions in visceral fat. CJC-1295 and ipamorelin have mostly been studied in animals or small human trials focused on GH levels, not on long-term health outcomes.
Some small studies have looked at combining a GHRH analog with a ghrelin secretagogue, such as CJC-1295 and ipamorelin. These studies suggest that the combination can increase GH levels more than either peptide alone. However, tesamorelin was not part of those studies, and its addition to the stack remains untested.
No published human trials have tested tesamorelin, CJC-1295, and ipamorelin together. Therefore, any claims about the benefits of this combination are speculative and not supported by rigorous clinical evidence.
Frequently Asked Questions
What is the tesamorelin CJC-1295 ipamorelin stack?
The tesamorelin CJC-1295 ipamorelin stack is a combination of three peptides that stimulate growth hormone release through different pathways. Tesamorelin and CJC-1295 act on GHRH receptors, while ipamorelin acts on ghrelin receptors. This stack is not FDA-approved and is not a standard medical treatment.
Is the tesamorelin CJC-1295 ipamorelin stack safe?
The safety of this specific three-peptide stack has not been established in clinical trials. Tesamorelin is FDA-approved for HIV-associated lipodystrophy, but CJC-1295 and ipamorelin are not approved for human use. Potential risks include injection site reactions, joint pain, increased blood sugar, and unknown long-term effects. Consulting a healthcare professional is essential.
What is the typical dosage for a tesamorelin CJC-1295 ipamorelin stack?
There is no standard dosage for this stack. Typical research doses for individual peptides are tesamorelin 1–2 mg daily, CJC-1295 without DAC 100–200 mcg 1–3 times daily, and ipamorelin 100–200 mcg 1–3 times daily. However, these are not clinically validated for stacking, and self-dosing is not recommended.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.